Freedom from thromboembolism despite prolonged inadequate anticoagulation
نویسندگان
چکیده
منابع مشابه
Anticoagulation for venous thromboembolism
Acute venous thromboembolism (VTE) is treated with parenteral administration of heparin or derivatives, in conjunction with oral vitamin K antagonists (VKAs) to reach and maintain INR values between 2.0 and 3.0 for at least 3 months; the duration of a further period of treatment for secondary prevention of recurrences is still matter of debate. If bleeding occurs during treatment the decision w...
متن کاملAnticoagulation after venous thromboembolism
Deep vein thrombosis and pulmonary embolism are two manifestations of the same disease, namely venous thromboembolism (VTE). Venous thromboembolism is a common disease with an annual incidence of 1–2 per 1000 person and a high short-term mortality rate of about 25% (1–3). A serious complication of VTE is recurrence, which is fatal in 3.6% to 10% of patients (4–6). In the majority of the patient...
متن کاملOptimal duration of anticoagulation after venous thromboembolism.
Case 1: A 79-year-old woman suffered idiopathic proximal right popliteal and calf deep vein thrombosis (DVT) 6 years previously. She had a normal hypercoagulability workup. Her warfarin has been managed successfully by a centralized pharmacist-run anticoagulation service, and she has easily achieved and maintained her target international normalized ratio range between 2.0 and 3.0. She has had ...
متن کاملLeft Atrial Appendage Thrombus Despite Anticoagulation.
The American College of Cardiology Foundation/American Heart Association task force on practice guidelines recommend therapeutic anticoagulation for at least 3 weeks prior to cardioversion in patients with atrial fibrillation of 48-hour duration or longer, or when the duration of atrial fibrillation is unknown. This case report demonstrates the presence of thrombi in the left atrial appendage d...
متن کاملThromboembolism and anticoagulation in pancreatic cancer.
Pancreatic cancer is a hypercoagulable condition, and venous thromboembolism affects up to 17% to 57% of pancreatic cancer patients. Initiating chemotherapy further increases the risk. For cancer patients initiating chemotherapy, there is currently no approved treatment for the primary prevention of venous thromboembolism risk. The authors summarize the two abstracts (#151 and #284) presented a...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Case Reports
سال: 2009
ISSN: 1757-790X
DOI: 10.1136/bcr.07.2009.2066